LianBio’s mission is to catalyze the development and accelerate availability of paradigm-shifting medicines to patients in China and major Asian markets through partnerships that provide access to the best science-driven therapeutic discoveries.Learn More
We are focused on building out a pipeline based on disease relevance to our target markets and the ability to impact patients with transformative mechanisms and precision-based therapeutics. We select programs with a strong scientific basis and clinical data and collaborate with world-class partners across a diverse array of therapeutic areas.
There are over 290 million people in China with cardiovascular disease and more than 100 million with chronic kidney disease. Cardiorenal disease is the leading cause of death in China today.
5.5 people die from cancer every minute in China alone and every year there are more than 4.5 million new cases diagnosed.
November 19, 2020
Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China
November 3, 2020
LianBio Announces Clearance to Initiate the Phase 3 PROOF Trial of Infigratinib in Patients with Locally Advanced or Metastatic Unresectable Cholangiocarcinoma with FGFR2 Gene Fusions in China
October 29, 2020
LianBio Announces $310 Million Crossover Financing
August 11, 2020
MyoKardia and LianBio Form Strategic Partnership to Develop and Commercialize Mavacamten Together in Greater China